# The Efficacy and Safety of Induction-Maintenance Protocol for Patients With Chronic Myelogenous Leukaemia

> **NCT03241199** · PHASE2 · UNKNOWN · sponsor: **The University of Hong Kong** · enrollment: 15 (estimated)

## Conditions studied

- Chronic Myeloid Leukemia
- Philadelphia Chromosome Positive CML

## Interventions

- **DRUG:** Imatinib Mesylate

## Key facts

- **NCT ID:** NCT03241199
- **Lead sponsor:** The University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-08-01
- **Primary completion:** 2020-06-13
- **Final completion:** 2021-01-01
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2017-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03241199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03241199, "The Efficacy and Safety of Induction-Maintenance Protocol for Patients With Chronic Myelogenous Leukaemia". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03241199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*